. While there have been decades of excellent and clinically informative research into understanding the signals that control regener ation of the normal liver 4 , the mechanisms at play when the abnor mal liver attempts regeneration are less well described 5 . Understanding how regeneration fails or is impaired in the severely damaged liver is an important goal. Lessons learned from relevant animal models might have impor tance in the clinical setting and aid the develop ment of new therapies to either promote regener ation or prevent complications that arise during the period of liver regeneration.
A clinical scenario in which an improved understand ing of regeneration of the compromised liver would be of benefit includes liver transplantation, here the increas ingly common use of partial liver grafts such as split livers and living donor transplants relies upon regener ation of the donor graft to reach the correct liver mass 6 . Failure of regeneration in these settings results in poor or delayed graft function, prolonged intensive care stays, occasionally a requirement for retransplantation or, ulti mately, even death of the recipient 7, 8 . By understanding the pathological mechanisms driving these adverse con ditions it is hoped that the period of regeneration can be more predictable and the associated clinical complications ultimately preventable. The ability to predict or improve liver regeneration when the liver is compromised -for example, in the setting of cirrhosis when surgical resection of hepatocellular cancer (HCC) is commonly performed, or following the resection of colorectal hepatic metastasis, when the liver has received prior chemotherapy -would enable clinicians to optimize cancer resection approaches. Furthermore, by understanding the mechanisms under lying normal liver regeneration and aberrant liver regener ation in chronic liver injury it is hoped that we will be able to promote 'healthy regeneration' or remodel ling in chronic liver disease. Such a scenario in which this approach could be applied includes liver cirrhosis. Here, the initial insult (such as viral hepatitis or autoimmune hepatitis) can sometimes be directly treated, but the liver tissue is left severely damaged and still susceptible to the clinical consequences of liver failure, portal hypertension and an increased risk of HCC 9 .
1
This Review cannot be comprehensive but seeks to describe briefly the mechanisms underpinning liver regeneration, the models used to study this aspect and then discuss areas in which failed or compromised liver regeneration is clinically relevant, with a view to highlighting areas for future research.
Mechanisms and models
In the following section we will review some of the animal models that have been used to understand liver regeneration. These have traditionally been in rodents (rats and mice), but new models are emerging such as the zebrafish (FIG. 1) . A general theme is that there has been much important work understanding how the normal liver regenerates in these models, but there is less information about how the damaged or compromised liver regenerates.
The rat model
The normal liver will attempt to retain an appropriate size relative to the rest of the body. Following injury or resection, the remaining liver undergoes a rapid series of coordinated changes to regain its original volume and structure 4 . Interestingly, this need to retain the previous size to body weight ratio occurs after liver hypertrophy has been induced by growth factors such as tri iodothyronine, when the liver shrinks back to its original size 10 .
The rat partial hepatectomy model is the classic model of liver regeneration and has been studied for decades. In a landmark paper published in 1931, Higgins and Anderson reported that removal of the two anterior lobes of the rat liver (the median and left lateral lobes) equated to a 70% reduction in liver size 11 . This stan dardized procedure is welltolerated and produces a reliable result. While the normal adult liver is mito tically quiescent with only minor hepatocyte proliferation detectable, following 70% or socalled twothirds partial hepatectomy the remaining liver remnant undergoes a series of rapid vascular endothelial, inflammatory and epithelial changes 4 (FIG. 2a) . The peak of liver regener ation, as measured by the number of hepatocytes in DNA synthetic phase, termed S phase, occurs ~24 h following resection 12 . By 7-10 days after hepatectomy, the rat has largely regrown a normalsized liver (93%) by hyper plasia of the remnant lobes, and by 20 days following hepatec tomy the liver has fully regained its starting volume 4 . This simple and repeatable experimental procedure has enabled many important new insights into regeneration of the normal liver 4 . Following such ' normal regener ation' the nonparenchymal cells in the liver, namely the hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECS) and macrophages, act in a coordinated fashion and help to control the epithelial regenerative response 13 . In a classic parabiosis experiment by Moolten and Bucher 14 , carotidtojugular cross circulation was established between rats that had been subjected to partial hepatectomy and normal non hepatectomized rats. This process induced liver regeneration in the non hepatectomized rats with normal livers and suggested fac tors were circulating from the hepatectomized rat to the normal rat to induce the regenerative response, pointing to circulating blood derived factors that help to stimulate and coordin ate liver regeneration following partial hepa tectomy 14 . IL6, TNF, hepatocyte growth factor (HGF), epidermal growth factor (EGF) and thyroid hormone have been discovered as humoral factors that control liver regener ation 15, 16 . Multiple important mechanisms controlling normal liver regeneration have been identi fied in the rat and have been wellreviewed elsewhere 4 in detail and will, therefore, not be discussed further.
The volume of liver resected in the rat can be increased to 90%, effectively modelling the clinical syn drome termed 'small for size' (REF. 7 ). In both the 90% hepatectomy model and the clinical situation, survival is compromised, with death from liver failure a major risk 17 . In the 90% hepatectomy model and the clinical situation, if the volume of resection increases beyond a threshold then the regenerative capacity of the remaining hepatocytes actually begins to decrease, thereby contrib uting to a rapidly developing scenario of liver failure 17 . Understanding why there is a failure of appropriate regeneration by the remaining liver is a clinically impor tant goal. The contributory mechanisms of this failure of regeneration are probably multiple, but an important factor is the vascular shear stress in the liver's sinusoids caused by the portal blood passing through a small paren chymal volume, which can cause peri portal sinusoidal endothelial damage and parenchymal inflammation 18 . Various strategies have been deployed in this model of 90% hepatectomy to increase liver regeneration and/or improve the survival following this operation. Ren et al. 19 showed that 90% but not 70% hepatectomy increased portal and systemic endotoxin levels. After this observation, they used selective bowel decontam ination with gentamicin and showed that this reduced lipopolysaccharide levels, enhanced liver regeneration and increased the survival following 90% hepatectomy from 24% to 56% 19 . Given that sepsis due to gutrelated microorganisms is a major cause of death after major hepatic resection 20 , this finding is potentially important. Another potentially clinically relevant treatment for this syndrome is octreotide. Octreotide is a splanchnic vaso constrictor and has been shown in a small study in the context of living donor liver transplantation to reduce
Key points
• Liver regeneration occurs efficiently in the normal liver to restore architecture, size and function; chronic injury severely impairs liver regeneration through excess inflammation, scarring and epithelial abnormalities, and is less well-studied but clinically important • New experimental models are emerging; zebrafish are an excellent new tool to study liver regeneration and enable large-scale chemical screening assays • A gap exists between current animal models of liver regeneration and clinically important scenarios of severe liver injury and impaired liver regeneration • Understanding and promoting regeneration and repair of the failing liver is a key challenge of major clinical importance • Modern imaging techniques will enable noninvasive real-time assessment of liver structure and function • Cell therapies that have been successful in animal models are now being trialled in the more challenging clinical arena portal venous blood flow and the hepatic venous pressure gradient, which could have beneficial effects given the elevated portal blood flow per liver volume discussed earlier 21 . Octreotide has been shown in the rat 90% hepa tectomy model to reduce mortality from 63% to 33% 22 . Interestingly, although octreotide had this beneficial effect on mortality, it actually reduced early hepatocyte prolifer ation. However, octreotide did reduce levels of liver injury and necrosis and modified the hepatic methionine cycle reaction, causing an increase in methionine and 5ʹmethyl thioadenosine, which was thought to be impor tant for the beneficial effect by being hepatoprotective to various liver injuries. This aspect was confirmed when 5ʹmethylthioadenosine administration alone was tested in the 90% hepatectomy model and improved survival, histology and remnant liver function. An important study by Ninomiya and colleagues 23 challenged the assumption that the promotion of regeneration would be beneficial in the rat 90% hepatectomy model. They hypothesized that the rapid regenerative response of small remnant liver is actually responsible for the poor outcome seen. They administered dHGF (a deleted variant of HGF), which promoted the rate of liver regeneration in the 70% hepatectomy model. However, in the 90% hepatectomy this factor had no benefit upon survival. Instead, they sought to delay the regenerative response through the administration of either NS398 (an ERK1/2 inhibitor) or PD98059 (a selective MEK inhibitor). Deceleration of the regenerative response by NS398 or PD98059 treatment resulted in a substantial and exciting improvement in day 7 survival (~70%) compared with the vehicletreated group (10%) 23 . Interestingly, the lobular spatial integrity was better preserved in hepatectomized animals that had their regenerative response lowered by NS398 than hepatectomized controls. Presumably, this step enables the portal blood flow and resulting physiological function to be maintained during the regenerative phase.
The rat has been widely used to study liver regener ation when the regenerative capacity of mature hepato cytes is compromised. Here, hepatocyte proliferation is inhibited by the chemical 2acetylaminofluorene. This approach can be combined with either partial hepatec tomy or the hepatotoxin carbon tetrachloride (CCl 4 ) to prompt liver regeneration 24, 25 . In a classic paper from the Thorgeirsson laboratory, [3H]thymidine was adminis tered to the 2acetylaminofluorenetreated rats at 6 days following partial hepatectomy. The [3H] thymidine labelled the only epithelial cells that were proliferat ing in the liver at this time, the oval cells, sometimes termed hepatic progenitor cells (HPCs). When the rats were subsequently sacrificed from 9 to 13 days, the [3H] thymidine was then identified in hepatocytes. Although not definitive proof that the oval cells or HPCs were the source of hepatocytes in the rat, this finding was suggest ive of a productprecursor relationship 26 . Later work in the rat 2acetylaminofluorene-partial hepatectomy model confirmed that cell proliferation was limited to the oval cells or HPCs and that hepatocytes were senes cent (that is, unable to proliferate) and p21 positive, making them an unlikely source of regeneration 27 . However, a report published in 2012 has challenged the concept that oval cells or HPCs contribute to liver parenchyma regeneration in the 2acetylaminofluorene-partial hepatectomy model in the rat and, following care ful observations, suggested that the replication of mature hepatocytes mainly contributes to regener ation of the liver, even in these circumstances in which hepato cyte regeneration is challenged 28 . Presumably, these hepato cytes, if able to regenerate, would have initially escaped the effects of 2acetylaminofluorene. Such results emphasize the need for reliable lineage tracing systems to make the claims of regenerative potential of various cell populations secure, but currently the transgenic technology to achieve this feat is poorly developed in the rat compared with mouse 29 .
The mouse models CCl 4 model. The mouse has been used as a model of liver regeneration, which has facilitated the use of the many mouse transgenic strains that enable the understanding of the role of various genes that control or modulate liver regeneration 30 . Transgenic mice can have a perma nent overexpression or underexpression of a normal or mutated gene, a refinement of this approach is that the gene can be conditionally deleted from a particular cell type in the liver at a set time (for example, before a partial hepatectomy) 30 . The physiology of regeneration in the mouse after partial hepatectomy is similar to the rat, although the peak of regeneration after this proce dure, as measured by bromodeoxyuridine incorporation into hepatocytes in DNA synthesis (S phase), occurs slightly later, at 24-48 h 31 . The mouse has been used to model liver regeneration in the setting of chronic liver damage in which normal liver regeneration is impaired. The most frequently used model of iterative liver damage is the chronic CCl 4 model of liver injury (which has also been used in the rat). Following CCl 4 parenchymal necrosis most prominently surrounding the central veins, peaking at 24 h, which is then followed by liver regeneration. After repeated dosing of CCl 4 , liver fibrosis begins to develop with the activation of HSCs into scarforming myofibroblasts, the deposition of excess liver scar tissue and, ultimately, the development of nodular liver cirrhosis. The collagen scar becomes increasingly crosslinked over time, making degrad ation of the scar more difficult and further inhibiting regener ation 1 . Upon cessation of CCl 4 administration, there is regeneration of the liver parenchyma, which is combined with scar degradation and resolution of the inflam mation 32 . In this setting, the importance of macro phages in collagen scar regression 33, 34 has been shown to be critical for effective liver regeneration 35 .
Dietary models. Several dietary models of liver injury in the mouse are commonly used to model liver disease, including the 1,4dihydro2,4,6trimethyl pyridine3,5dicarboxylate (DDC) diet 36 , which induces biliary injury and regeneration. While taking the DDC diet, there is a proliferation of primitive ductules with poorly defined lumens that spread from the portal tract into the hepatic lobule in the mice. This ductular reaction is associated with marked fibrosis 37, 38 and thus is a model of biliary injury and fibrosis. Mice subjected to the DDC diet respond poorly to partial hepatectomy as their regenerative response is decreased 36 . Another diet model that is commonly used in mice is the modified cholinedeficient ethionine diet devel oped by the Yeoh Group 39 , which induces hepato cellular injury with a degree of steatosis and a secondary ductular response in which ductular cells (broadly com parable to oval cells in the rat) spread from the portal tract 37, 40, 41 . These ductular reactions are important for biliary regener ation after injury and, if their prolifer ative response is impaired following biliary injury, then there is an increase in hepatic necrosis 42 . Whether the ductular reactions contain bipotential HPCs capable of regener ating hepatocytes as well as biliary cells is a controver sial area. In mouse models, in the absence of marked hepato cyte senescence, hepatocyte self replication seems to prov ide practically all hepatocyte regeneration with little or no contribution from HPCs 43, 44 . However, in the context of severe liver injury and hepatocyte replica tion failure, HPCs might have hepatocyte regenerating capacity 45 . The degree and importance of this axis in severe liver injury needs further study and might require the development of models in which hepatocyte replication can be inhibited to model the severe human liver disease.
The zebrafish model
Zebrafish have been developed in the past few years to model many diseases and provide insights into patho physiological processes 46 (FIG. 1) . Their small size and optical translucency brings the advantages of low cost and rapid analysis via microscopy 46 . As they grow in water, zebrafish have been used as a model system for in vivo chemical screening with the small molecules to be tested added to the water 46, 47 . To date, their use has shown that many of the biological processes and signal ling pathways seen in the mouse and rat are recapitulated in zebrafish 46 . Liver generation can be provoked in zebrafish in a numbers of ways, including surgical partial hepatectomy, druginduced liver injury and nitroreductose mediated hepatocyte ablation 47 . The zebrafish has a trilobar struc ture and the onethird partial hepatectomy model has been established in the zebrafish by removal of one lobe 48 . Clearly, this approach is currently a more limited resec tion than performed in rat and mice. These studies have established signals such as Wnt 49 , bone morpho genetic protein and fibroblast growth factor as important for liver regeneration in zebrafish 50 . Interestingly, zebra fish exhibit cellular plasticity in that bile ducts can convert to hepatocytes following largescale hepatocyte loss. Two independent reports found, using hepatocyte ablation and lineage tracing, that following extensive hepato cyte loss the biliary cells are able to regenerate the hepato cytes 12, 51, 52 . Interestingly, in an ethanol induced model of liver fibrosis, Huang et al. 53 found that Wnt and Notch have opposing roles in directing HPCs in their regener ation of hepatocytes. Low levels of Notch stimulation activated HPC proliferation and hepatocyte differen tiation, high levels of Notch suppressed this pathway. Wnt ligands were found to suppress Notch signalling via Numb, a protein inhibitor of Notch 53 . Importantly, this finding helps to validate the zebra fish model in the liver regeneration setting, as the same opposing signals (Wnt and Notch acting via Numb) have previously been shown to control the behaviour of HPCs in mice and are differentially expressed in hepatocellular versus biliary injury in human liver 40 . Zebrafish are an ideal model for socalled forward genetics due to their small size and ability to screen large numbers of organisms following exposure to a chemical mutagen: phenotypes can be screened and the actual gene/s responsible then mapped -an approach that has already yielded results in the setting of liver development 54 . This exciting new model system looks set to make important inroads, especially into the area of screening compounds and drugs for their effects upon liver regener ation. However, we should still express some caution and there is an important need to show that the signals and targets identified translate through into mammalian systems, including human liver regeneration.
Determining cellular sources and mechanisms
As discussed earlier, in mouse models of liver injury, the latest lineage tracing experiments have failed to show convincing regeneration from non hepatocyte sources 43, 55 unless there is substantial liver injury and hepato cyte prolifer ation is strongly inhibited 45 . Furthermore, evidence exists that hepatocytes can undergo a ductular change and at least partly contribute to the ductular cell popu lation 56, 57 . However, as already outlined, in zebra fish there is strong evidence using line age tracing systems that ductular cells and/or HPCs can give rise to notable hepato cyte regeneration after marked liver injury 12, 51, 52 . In the rat, there is some circumstantial evidence suggest ing that oval cells can regenerate hepato cytes when hepato cyte regeneration is compromised 26 ; however, opposing data does exist suggesting that this regener ative pathway is not substantial 28 . A common theme is the need for reliable lineage tracing systems to provide proof of the regenerative line ages in the models commonly studied, a further issue is whether the liver injury systems reliably recapitulate the severity of liver injury seen in human disease. Morphological studies have claimed that HPCs regener ate hepatocyte 'buds' in areas of liver parenchyma that have been obliter ated 58 . However, per forming lineage tracing experiments in humans is not possible and caution is required in interpreting such studies. The nearest approach to lineage tracing in the human liver is the use of mitochondrial DNA mutation analysis to show that regenerative nodules and adjacent ducts can be clonal 59 . Although an important observa tion and a technical 'tour de force' , this finding does not conclusively prove any precursor-product relationship. Understanding the cellular contributions to hepatocyte and biliary regener ation might seem an academic exer cise and remote from clinical practice. However, defining the regenerative cells in clinically relevant models of liver injury and regeneration will considerably aid the development of strategies to promote liver regeneration, either through cell therapy or through the stimulation of endogenous repair and regeneration.
Bile acids and liver regeneration
Bile acids have now been recognized as important for liver regeneration, as Ueda et al. 60 showed that liver regeneration is impaired in rats in the absence of intestinal bile. Following this report, it was shown that increased bile acid levels accelerate regeneration, while low levels of bile acids impair regeneration in vivo, as does absence of the bile acid receptor (also known as farne soid Xactivated receptor or FXR) 61 . Bile acids are rapidly increased following partial hepatectomy and signal via the receptors FXR and Gprotein coupled bile acid recep tor 1 (GPBAR1, also known as TGR5). FXR signalling reduces liver injury and promotes liver regeneration follow ing CCl 4 induced liver injury 62 . The potential clin ical application of these basic studies was indicated by Otao et al. 63 , who analysed liver regener ation in patients following extended hemihepatectomy and found that patients who had external biliary drainage had lower levels of liver regeneration than those patients without external biliary drainage. This study was retrospective and there might be confounding factors (such as case selection) that could explain the striking results, how ever, further studies into this area are warranted. This interesting finding highlights a general point, that pro spective trials are warranted in the clinical setting for which there is strong animal data indicative of efficacy, and for which there is an acceptable risk:benefit ratio from a new intervention.
Gap between animal models and clinical data Both animal models and clinical studies are informative, but there still remains a gap between the basic under standing of the mechanisms that drive regeneration in animal models and the implementation of this under standing to the human clinical situation for therapeutic benefit (TABLE 1) . Ideally, to maximize the development of understanding of liver regeneration and develop new techniques to enhance liver regeneration, observations made using in vivo models should inform human stud ies and the human studies should feedback to refine the in vivo models.
At one end of this 'bridge' , animal models have been highly informative regarding the drivers of liver regener ation, the timing of response and cellular sources of the regenerative cells in the liver. Through the use of modern cell and molecular biology techniques, combined with modern transgenic mice and now zebrafish technology, the signalling and cellular mechanisms underpinning liver regeneration are rapidly being described. At the other side of the 'bridge' , human clinical studies of liver regeneration have, by necessity, often included patients who have a heterogeneous collection of liver insults 64 . The studies have primarily examined clinical outcome and sought to define associations of poor outcome and preoperative markers of poor outcome. The study tech niques have often revolved around wholeorgan imaging and serum analysis without ready access to liver tissue.
This combination of factors means that the clinical stud ies have generally been less able to offer the mechanistic insights that animal research affords.
To date, there is still a marked gap between these areas of study, with the signalling mechanisms rarely trans lating to clinical trials or indeed human observational studies, and thereby rarely having any effects in clin ical practice. Likewise, the human observational studies can provide little data to support further discriminatory in vivo studies. Noninvasive measurements during liver regeneration in patients should be particularly insight ful in the future. Modern functional imaging tech niques, such as magnetic resonance spectro scopy [65] [66] [67] , in which distinct meta bolic signatures are seen in patients with regenerating livers, should have an effect on the trans lational gap. Likewise, proteomic analy sis of patient's blood during liver regeneration seems an obvious future development; studies in mice have already shown a distinct proteomic signature in plasma following hepatectomy and during liver regeneration that were strongly associ ated to metabolism 68 . Another noninvasive method of analysis is the 13 Cbreath tests, which can measure hepatic mitochondrial, microsomal and cytosolic function 69 . The 13 Cphenylalanine breath test has been used in a rat model of 70% hepatectomy and showed good discrimination between rats that had undergone 70% hepatectomy and sham controls at 24 h postsurgery, indicating possible future clinical utility 70 . These techniques all show promise and might help to build strong links between the in vivo models and human studies, and indeed enable further refinement of the current in vivo models.
Regeneration in the 'abnormal' liver
In the clinic, the regeneration of normal liver is rele vant; for example, when a healthy relative donates part of their liver to a recipient with liver disease, socalled living donor liver transplantation. Here, the donor will have been specifically screened to exclude clinically significant liver disease 71 . However, in the majority of clinical scenarios the abnormal, damaged liver is the one required to perform the feat of regeneration. The challenges to regeneration are very different across the different clinical scenarios and some of these are detailed in this section.
Severe acute liver damage and fulminant liver failure Common causes of acute liver failure include viruses such as hepatitis A virus, HBV and hepatitis E virus, drugs such as paracetamol (also known as acetamino phen) and autoimmune liver disease 3 . By definition, in acute liver failure, the liver was previously normal and the damage acute, often with widespread hepato cyte apoptosis and necrosis 3 . Following experimental moder ate liver injury and necrosis, there is proportional hepatocyte proliferation until homeostasis is achieved 4 . However, with increasing injury a threshold is reached beyond which the remaining liver fails to regenerate adequately. This finding has been clearly shown by Bhushan et al. 2 in mice that, compared with a moder ate dose of paracetamol (300 mg/kg), a higher dose (600 mg/kg) actually resulted in poorer liver regener ation in the nonnecrotic parts of the liver. Attempts have been made to translate findings in animals and identify targets to potentially stimulate liver regener ation in humans following acute liver injury. For example, in mice, using the paracetamol model of liver injury, loss of βcatenin activation prevents liver regener ation 72 . In patients with paracetamolmediated liver injury, the degree of βcatenin activation correlated with the degree of liver regeneration, indicating that βcatenin activation could be a possible therapeutic strategy in patients with acute liver injury 72 . In the setting of acute liver injury, the innate immune system is critical for coordinating and stimu lating regener ation, as well as for maintaining immunity 13 . In particular, macrophages are important for the phagocytosis of the necrotic tissue and the stimulation of liver regeneration 73 . Following paracetamolinduced liver injury, macrophages are rapidly recruited to the areas of liver necrosis 73 . Mice deficient in macrophage colony stimulating factor 1 (CSF1), a cytokine that promotes the maturation of haematopoietic stem cells into macro phages and stimulates their phagocytic activ ity, have reduced numbers of tissue macrophages and an impairment in liver regeneration, which can be overcome by the addition of exogenous CSF1 (REF. 74 ). As well as helping to coordinate a liver regeneration response, the hepatic macrophages are important in controlling sepsis, a major complication of acute liver failure that is associ ated with clinical deterioration, systemic inflammatory (FIG. 2) , are a major filter of por tal blood and are particularly important when the gut barrier function is compromised in liver failure. CSF1 levels are related to prognosis in paracetamolinduced fulminant liver failure and, in experimental models of acute liver injury, the exogenous administration of CSF1 has been used to boost immunity and the phagocytic function of hepatic macrophages 75 .
Fatty liver
Dietaryinduced hepatic steatosis reduces liver regener ation after 70% hepatectomy in rats 76 , and patients with obesity regenerate their livers more slowly than individ uals without obesity as controls 77 . Given the increasing global incidence of fatty liver disease 78 , it is not surpris ing that the impaired regeneration of fatty livers is an increasingly important clinical question.
In liver transplantation, the presence of macro scopic hepatic steatosis can have serious consequences and increase the risk of primary graft nonfunction 8 , the more severe the steatosis then the greater the risk of hepatic dysfunction. A proportion of potential liver donor grafts have to be discarded if they are too fatty, as above a threshold of steatosis there is an increased risk of graft failure upon transplantation 79, 80 . The assess ment of steatosis can be made by the surgeon at the time of organ procurement, but has an inbuilt subjective element. A pathologist can quantify hepatic steatosis on biopsy, but this step is not always convenient and, of course, is from a limited sample area. Imaging methods are therefore being trialled as a way of objec tively quantify ing hepatic steatosis. A CT assessment of the donor liver was tested in 109 consecutive cadaveric donors and the cadaveric liver:spleen attenuation ratio determined. All donor livers had a biopsy and blinded pathological assessment. Use of the CT scan was able to predict clinically significant steatosis (defined as >30%) with a sensitivity of 79% and a specificity of 97% 81 , indicating its potential future utility. Another noninvasive method of assessing hepatic steatosis in donor grafts that shows promise in animal models is Raman spectro scopy, and this technique will probably be studied further in the human liver 82 . The study of factors inhibiting liver regeneration in the context of fatty liver is likely to be a subject of increasing clinical relevance. Experimentally, growth arrest and DNA damageinducible protein GADD34 (GADD34, also known as PPP1R15A) inhibition was shown to be an important factor impairing regeneration of the fatty liver, and GADD344 overexpression through gene therapy increased liver regeneration in mice with fatty liver 83 .
Small liver grafts, IR injury and RAGE
The transplantation of small grafts relative to the recipi ent can result in socalled small for size syndrome (SFSS). Several putative pathological mechanisms are thought to be causative in SFSS, including excessive portal blood inflow causing intrahepatic vascular shear stress 84 . SFFS results in a combination of injury in the liver and poor regeneration of the graft 85 . The clinical presentation often includes liver failure, coagulopathy, ascites, cholestasis and encephalopathy. Although the mainstay of management is prevention by careful vol ume analysis, surgical techniques are being developed to reduce the incidence of this serious but thankfully rare condition 7 . Ischaemia-reperfusion (IR) injury is a major issue affecting transplanted livers 86 . The molecular and cellular pathogenesis of this condition is beyond the scope of this Review but has been extensively reviewed elsewhere 87 . Receptor for advanced glycation end products (RAGE) is markedly increased in mice with hepatic IR injury 88 . Two important studies have shown that RAGE is a potential therapeutic target. In a mouse model of IR, blockage of RAGE signalling reduced liver injury and increased regeneration 88 . In a mouse model of hepatectomy, RAGE was increased in mice that had undergone 85% hepatectomy, compared with mice that had undergone 70% hepatectomy 89 . RAGE was expressed in dendritic cells, specifically mono nuclear phagocytederived dendritic cells. Blockade of RAGE reduced hepatocyte death, increased regener ation and increased survival in the 85% hepatectomy mice from 30% to 90% 89 . In patients with paracetemol induced acute liver failure, increased circulating levels of soluble RAGE (sRAGE) was found to be associated with liver transplantation or death rather than spon taneous recovery 90 . Future therapy might be indicated by a study in mice in which reduced hepatic IR injury by prior treatment with the drug losartan (an angio tensin II receptor antagonist), which increased peroxi some proliferatoractivated receptorγ signalling and reduced RAGE activation 91 . Clearly, the early detection and quantification of the liver's metabolic status to pre dict posttransplant IR might enable therapeutic trials and interventions. Ex vivo spectroscopy of the organ could be performed to gain a realtime assessment of the meta bolic status of the graft a nd facilitate possible preconditioning interventions 65 . Although an inter esting future technique, it is technology and operator intense and at present time this aspect might limit widespread uptake.
Abnormal and excessive extracellular matrix
Activation of quiescent HSCs (pericytes) into activated scarforming myofibroblasts leads to excessive deposi tion of extracellular matrix 92 (FIG. 2b) . This aberrant scar formation in the liver has been shown to inhibit hepato cyte proliferation 1 . The collagen scar also needs to be remodelled for the formation of a ductular response 35 . The relationship between the ductular reaction, which occurs during times of impaired regeneration, and fibro sis is complex as an extensive ductular response is also commonly associated with a rapid fibrotic response 38 . After cessation of injury, the scar tissue can be degraded and hepatic macrophages are thought to be key cellular mediators of this action 33 , secreting matrix metallo proteinases that can degrade scar tissue 33, 93 . If liver injury and scarring progresses, then eventually bridg ing fibrosis and the appearance of regenerative nodules occur. In this setting, vascular abnormalities develop and the blood flow to the liver switches from being predomin antly from the portal vein to predomi nantly from the hepatic artery; that is, becomes arterialized. The liver's epithelial cells -hepatocytes and biliary epi thelial cells -become increasingly senescent (unable to divide) 94 . In this setting, removal of the injurious agent is the key goal to promote endogenous liver repair, but there is evidence that the addition of additional ex vivo cell therapies such as macrophages might promote the endogenous repair by increasing the resolution of liver fibrosis and promoting liver regeneration 34, 95, 96 .
Cirrhosis and chronic liver injury
Liver disease is often asymptomatic initially and patients can present to liver physicians with estab lished cirrhosis. Often the injurious insult can be removed (such as the treatment of hepatitis C, cess ation of alcohol or treatment of an autoimmune dis ease). However, patients are on a precarious tightrope with very small changes leading to decompensation and frequent hospital admissions with decompensated liver cirrhosis 9 , likewise natural history studies clearly show that some patients can recompensate at this stage and not require further inpatient hospital treatment. By providing a stimulus to the natural regenerative pro cess, this treatment is targeted to a patient group who will benefit hugely from a successful strategy to improve liver regeneration.
Even in cirrhosis, if the injurious insult can be treated then the liver can regenerate and remodel to some degree. D' Ambrosio et al. 97 showed in a paired biopsy study in patients with HCVinduced liver cir rhosis who had been successfully treated for HCV infection that after 61 months from viral eradication (sustained virologic response), cirrhosis regression was observed in 61%, and the collagen content decreased in 89%. Critically, regression of cirrhosis can lead to a reduction in hard clinical endpoints (such as compli cations or death) 98 . This finding clearly indicated that even in the context of liver cirrhosis the natural his tory can be modified and patient outcome improved. With the new, exciting and effective antiviral treat ments for hepatitis C, there will be many patients with HCVinduced cirrhosis who have been cleared of virus and have nonprogressive disease but who are still at high risk of clinical events and decompensa tion; these individuals will benefit greatly from treat ments that improve liver regeneration and background liver function.
The requirement for regeneration is even greater when considering liver resection for HCC in the setting of a patient with cirrhosis, as the baseline liver func tion is already compromised presurgery. However, the acute nature of the surgical resection gives little time for regeneration and decompensation post resection can occur based upon the liver reserve presurgery and the size of resection. The presence of portal hyper tension increases this risk of decompensation but not as an absolute contraindication to resection in selected cases 99, 100 . For patients with liver cirrhosis and HCC, the optimal therapy is often transplanta tion provided the disease is not too extensive and falls within the transplant programme's agreed criteria based upon the size and number of tumours, for example the Milan Criteria 101 .
Clinical measurement of liver regeneration
Much of the literature on measurement of human liver regeneration relates primarily to liver resection and liver cancer, and to a lesser extent to acute liver fail ure. Consequently, measures of volume replacement or recovery from very low levels of hepatic function ality (as seen in acute liver failure) have received more attention. The advent of new therapeutic strategies, and in particular their use in the setting of chronic liver damage, will require additional measures of liver regeneration that more appropriately reflect the less profound changes, albeit still clinically relevant, that might occur (FIG. 3) .
Clinical symptoms and signs of liver dysfunction
For the patient with compensated liver cirrhosis it is unlikely that there will be any notable symptoms or signs that can be used as a measure of regeneration. Symptoms that exist in this setting are often less precise, such as fatigue, subclinical hepatic encephalopathy or muscle weakness, and can sometimes be multi factorial in origin. Nevertheless, such parameters can be meas ured using validated questionnaires and might provide clues to the effect of an intervention [102] [103] [104] . For patients with more advanced chronic liver disease there will be more overt features of liver dysfunction (hepatic encephalopathy, jaundice, ascites) that can serve as a point from which to measure improvement in liver function (regeneration). This evaluation can range from a categorical assessment (clearance of ascites Strategies to improve liver regeneration include the removal of injurious agents, the promotion of fibrosis resolution and the direct stimulation of hepatocyte proliferation. The balance between these two sets of processes is key in determining the clinical outcome. GCSF, granulocyte colony-stimulating factor; HSC, hepatic stellate cell; MSC, mesenchymal stromal cell; T 3 , thyroid hormone.
and/or encephalopathy), to subjective semiquantitative scores (grades of ascites or encephalopathy), through to a more formal model such as the modified Child-Pugh score. The Child-Pugh Score, which encompasses both objective (bilirubin, albumin, international normal ized ratio (INR)) and subjective (hepatic encephalo pathy and ascites) assessments of liver dysfunction, generates a numerical value to reflect the state of liver dysfunction. This scoring system was originally valid ated as a prognostic tool to predict mortality during surgery for patients with liver cirrhosis 105, 106 , although it is now more commonly used to determine overall patient prognosis.
Blood measures of liver regeneration
Simple measures of regeneration include measure ment of the cancer neoantigen alphafetoprotein (AFP) in serum. The rate of increase of serum AFP has been shown to correlate with survival of patients with acute liver failure 107 , although its utility in the set ting of chronic liver disease is not established. Higher serum levels of miRNA (miR)122, miR21 and miR221 have been reported in patients spontane ously recovering from acute liver failure due to a range of aetiologies, as compared with patients that did not recover 108 . Additionally, patients with elevated serum miR levels displayed increased hepatocyte prolifer ation and downregulation of hepatic miRNA target genes that impaired liver regeneration 108 . Published in 2012, the Acute Liver Failure Study Group (ALFSG) index was established and compared with the long standing King's College criteria (KCC) and MELD (Model for Endstage Liver Disease). Hepatic coma grade, INR, serum bilirubin level, serum phosphorus level and serum M30 level value accurately identified patients that would require liver transplantation or die. The ALFSG index identified these patients with 85.6% sensitivity and 64.7% specifi city. The ALFSG Index was superior (AUROC 0.822) to KCC (AUROC 0.654) or MELD (AUROC 0.704) (P = 0.0002 and P = 0.0010 respectively) in identifying patients that would require liver transplantation 109 . Recognizing the potential limitation of scoring systems such as Child-Pugh score, which include sub jective assessments, the MELD scoring system was developed in 2000 and consisted of bilirubin, creatinine and INR 110, 111 . The ability of MELD to predict prognosis of patients with liver cirrhosis has been validated in many studies across a broad spectrum of liver disease. Prognosis can be deduced from the absolute value as well as a change in MELD over a defined timeperiod such as 3 months 112 , which might be of particular rele vance for the assessment of new therapies in which a positive or negative change in the MELD score would be informative. Studies using MELD as an outcome measure will need to determine the durability of any observed change as well as establishing if it has the same clinical prognosis.
Less often used tests for liver function include those that test the ability of the liver to metabolise adminis tered chemicals, such as the erythromycin breath test 113 and caffeine elimination rate and clearance 114 . Other tests measure hepatic circulation using test compounds with flowdependent, high firstpass hepatic extraction such as galactose (galactose elimination capacity 115 and cholate clearances and shunt 116 . Although attractive candidates to assess response to a treatment, the clin ical validity of these parameters has yet to be estab lished and thus the clinical importance of any change remains uncertain.
Imaging assessment of liver regeneration
In the setting of liver resection, the rate at which liver volume recovers is commonly used as a measure of regeneration, and can be undertaken with a range of imaging modalities including CT, MRI and SPECT (singlephoton emission CT) scanning (TABLE 2) . The relevance of this fairly crude measure of regeneration is not entirely clear in the setting of more subtle inter ventions and thus new approaches are needed. In the setting of chronic liver disease, imaging modalities are being increasingly used to determine the extent of liver fibrosis through assessments of liver stiffness 117 . Resolution of liver fibrosis is probably an impor tant therapeutic target when trying to promote liver regener ation. These include ultrasonographybased modalities (Fibroscan, Echosens, France), which are widely used in clinical practice 117 , as well as CT and MRI approaches, which might be superior in their ability to provide a more global assessment of fibrosis and hence enable identification of more subtle changes. Dynamic contrast enhanced CT (DCECT) and MRI (DCE MRI) imaging and more recent MRIcompatible tech niques enable 118,119 measurement of hepatic perfusion and, in the context of liver cirrhosis, might be able to estimate the extent of portal hypertension, which is commonly elevated in this setting. A commonly used measure is the hepatic perfusion index, which is cal culated by estimating the slope of arterial perfusion divided by the sum of the slope of the arterial and por tal perfusions 120 . The ability to noninvasively measure portal hypertension would be an important outcome although, as yet, this step has not been achieved. Portal hypertension represents a clinically relevant parameter against which the effectiveness of new therapies can be judged and is accepted as a licensing endpoint by regulatory authorities.
The future
The most immediate developments will probably focus on noninvasive assessment of portal hypertension, which will represent a major step forward. However, the development and validation of new noninvasive tests to inform on early signals of hepatocyte turnover and fibrosis remodelling is also required.
Management and therapeutic targeting
Regenerative mechanisms are present during liver injury, even after chronic damage, but in many cases they are insufficient to overcome the ongoing insults, necessitating additional measures to be explored (TABLE 3) .
Reduction or removal of injurious process
In many cases, the optimal method to promote liver regeneration is to either stop or interfere with the injur ious process. Mostly, this approach involves stopping or reducing the aetiological factors, such as alcohol cess ation or losing weight, or, in the case of viral hepa titis, treatment with new antiviral medications that have had major positive effects on disease progression and/or res olution 121, 122 . In many situations though, no effective treatments are available (such as NAFLD 123 or auto immune liver disease 124 ), or patients continue with detrimental environmental factors (such as continu ing to consume alcohol or gain weight in the context of NAFLD) and therefore in these settings additional interventions are needed to promote liver regeneration. Moreover, there are occasions in which, even after the injurious agent has been removed, the residual liver damage is so advanced, and/or continues to progress such that adjunctive measures are needed 9 . In many forms of liver disease there is a super imposed immunedriven component to the ongoing liver damage, leading to strategies to modulate immune responses in this setting. This approach has taken the form of either pharmacological agents to reduce lympho cyte ingress to the liver as well as cell therapy approaches to reduce the activity and ingress of inflammatory cells in a bid to resolve the original insult 125 .
Encouraging endogenous liver regeneration
In the setting of chronic liver disease, hepatocyte prolifer ation is impaired, and the presence of liver fibro sis is recognized as a major factor inhibiting hepato cyte proliferation 1, 32 . Thus, approaches to reduce liver fibrosis as discussed here might be effective in pro moting liver regeneration. Other strategies include the use of pharmaco logical agents or cytokines to stimu late hepato cyte proliferation. Granulocyte colony stimulating factor (GCSF) has been used extensively in preclinical models in which it has been demonstrated to stimulate proliferation of endogenous hepato cytes, resulting in both reduced liver damage and less fibrosis 126 . GCSF has also been demonstrated to increase both the proliferation and motility of HPCs in the experimental setting 127 , which might in turn also aid regener ation. However, there still remains uncertainty about the efficacy of GSCF in liver dis ease with the majority of clinical studies being small in nature and not powered to confirm efficacy. A notable exception relates to a random ized controlled trial in acuteonchronic liver failure, in which GCSF 128 . The mechanism of this effect was not established, although the study authors specu lated that GCSF might improve neutrophil function, which is commonly diminished in the setting of chronic liver disease. Thyroid hormone (T 3 ) has been demon strated to be a strong inducer of liver cell proliferation in rats and mice 10 , and studies have shown that the hepato cyte mitogenic response is mediated by PKAdependent βcatenin activation 129 . Enthusiasm for T 3 is reinforced by the observation that its administration helps inhibit and/or reverse NAFLD 130 and reduces the risk of hepatic tumour development in rat models 131 . T 3 administra tion has been used in rats before 90% hepatectomy and increased survival from 14% (controls) to 57% 132 . An important concern when the promotion of endogenous regeneration is considered is the potential development of HCC, which is pertinent in the context of cirrhosis when the risk of HCC is raised and there is frequently activation of the ductular compartment. The cellular origin of the HCC is therefore a consideration. Importantly, in two mouse models of HCC, data shows that the cancers arose from lineagetraced hepatocytes rather than the biliary or progenitor compartment 133 . On the basis of this data one must be cautious that the promotion of hepatocyte proliferation could theoreti cally increase the risk of HCC, although we should not over interpret this aspect when extrapolating from speci fic mouse models to the human scenario. The impor tant study by Ninomiya et al. 23 in the 90% hepatectomy model raises the idea that when there is a small liver remnant and substantial liver volume gain is required, then controlling the rate of liver regeneration and thus minimizing architectural and sinusoidal disorganisation is a valuable concept that might be worth translating toward the clinic.
Degradation of fibrosis
Extensive investigations of potential effective anti fibrotic agents in preclinical models of liver disease, predominantly in the CCl 4 model, have been performed. Resolution of liver fibrosis is known to be more difficult in its more advanced stages, and therefore uncertain ties about the generalizability of preclinical models such as CCl 4 to the clinical situation of liver cirrhosis have arisen. One of the other major challenges in the trans lation of such agents into the clinical arena is the lack of any satisfactory noninvasive methods to quantify liver fibrosis with sufficient sensitivity to detect modest, but clinically and biologically important changes. Hence, liver biopsy is currently relied on for measurement of fibrosis, which poses substantial logistical issues such as the risk of postbiopsy infections and bleed ing in patients with reduced immunity and potentially coagulo pathy. Nevertheless, several antifibrotic drugs have been studied in earlyphase clinical trials 134 with no compelling signal for efficacy seen with colchicine Cell therapies have also been studied in pre clinical models of liver fibrosis, with macrophages 139 , bone marrow 140 and mesenchymal stromal cells 141 all having demonstrated efficacy in models of CCl 4 induced liver fibrosis (TABLE 3) . Smallerscale clinical studies (typically in patients groups from 2 to 30) in patients with chronic liver disease have also suggested reductions in liver fibro sis alongside improvements in liver synthetic function 142 . These studies have predominantly used haemato poietic stem cells or mononuclear preparations that have either been harvested from bone marrow or mobilized into the circulation by the use of GCSF, which as indicated earlier, might have additional beneficial effects on liver regeneration. Although these improvements in synthetic function came from small nonpowered studies, there was little to suggest any substantial safety concern, with the exception of when cells were infused intraportally 143 . In that setting, there was an increase in portal hyperten sive bleeding, which serves as a caution for such routes. Indeed, homing of stem cells to the liver is enhanced after liver injury 144 and, given that trial data do not suggest superior efficacy with liverdirected infusions, logistically easier routes can be used. To determine the mechanisms by which these potential effects are achieved in the clinical setting requires further investi gation, as does their confirmation in larger clinical trials. To date, no adequately powered randomized trials of cell therapy have shown a positive effect 145 .
Conclusions
Liver regeneration in the normal liver is well described in validated model systems, such as the rat and mouse partial hepatectomy models. The cellular and signal ling mechanisms described using these models have provided a general template for understanding liver regeneration and to plan therapeutic interventions. New models such as the zebrafish are bringing the ability to rapidly screen compounds for their ability to improve liver repair and regeneration following injury.
In the clinical setting, the deficiencies of regener ation usually have a negative effect when there is a grossly abnormal liver architecture, or when normal liver regeneration is severely impaired. Understanding the abnormal regenerative responses and how they dif fer from normal healthy regeneration will be critical to accurately targeting new therapies. Such strategies might have several broad targets such as excessive fibrosis, abnormal ductular responses and the impaired innate immunity, which are a feature of liver dysfunction. Advances in imaging technology, such as MRI combined with liver spectroscopy, might provide a more complete picture of the liver volume and anatomy, liver blood flow data, measures of wholeliver fibrosis and wholeliver signatures of metabolic function, which could provide a holistic picture of structure and function of the liver to guide surgical resection and other therapeutic decisions. Overall, we conclude that, when there is good animal data of efficacy for a particular intervention, and there is an acceptable riskbenefit ratio, then the time is right to translate this knowledge and perform appropriate prospective clinical studies.
